Skip to main content
MedPathMedPath Home
Clinical Trials/NCT03761758
NCT03761758
Completed
Not Applicable

Tolerability of a Novel Spectacle Design With Reduced Peripheral Contrast

SightGlass Vision, Inc.1 site in 1 country21 target enrollmentMay 1, 2018
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsMyopia

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Myopia
Sponsor
SightGlass Vision, Inc.
Enrollment
21
Locations
1
Primary Endpoint
Distance Visual Acuity
Status
Completed
Last Updated
7 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSitesSimilar Trials

Overview

Brief Summary

Prospective, randomized, subject-masked 3-arm clinical study to assess the pediatric acceptability across three iterations of a novel spectacle lens design.

Detailed Description

This feasibility study was conducted to assess the performance of three experimental spectacle lens designs (spectacle lenses) in children between 6 and 9 years of age with myopia.

Registry
clinicaltrials.gov
Start Date
May 1, 2018
End Date
July 19, 2018
Last Updated
7 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • •Ages between 6 and 12 years
  • •Myopia between -1.00 and -4.00 D

Exclusion Criteria

  • •Participating in any clinical or other research study
  • •Contact lens wearer

Outcomes

Primary Outcomes

Distance Visual Acuity

Time Frame: 2 weeks

Measurement of best corrected distance visual acuity

Subjective Responses

Time Frame: 2 weeks

Assessment of subject responses related to wear time of spectacles

Contrast Sensitivity

Time Frame: 2 weeks

Measurement of contrast sensitivity

Study Sites (1)

Loading locations...

Similar Trials

Completed
Phase 3
A Randomized Trial of Base-in Prism Reading Glasses Convergence Insufficiency in ChildrenConvergence Insufficiency
NCT00347581Pennsylvania College of Optometry72
Active, not recruiting
Phase 1
Acceptability study of a new paediatric form of vigabatrin in infants and children with infantile spasms or pharmaco-resistant partial epilepsy.Infantile spasms and pharmaco-resistant partial epilepsyMedDRA version: 18.0Level: PTClassification code 10021750Term: Infantile spasmsSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 18.0Level: LLTClassification code 10065336Term: Partial epilepsySystem Organ Class: 10029205 - Nervous system disordersTherapeutic area: Diseases [C] - Nervous System Diseases [C10]
EUCTR2014-000360-17-FRTARGEO
Completed
Not Applicable
Acceptability study of a new paediatric formulation of Orphacol® (cholic acid) in paediatric patients treated for inborn errors in primary bile acid synthesis due to 3ß-Hydroxy-?5-C27- steroid oxidoreductase deficiency or ?4-3-Oxosteroid-5ß-reductase deficiency.K76.8Other specified diseases of liver
DRKS00013645aboratoires CTRS4
Completed
Not Applicable
Surgical Treatment of Children With OSA and Small Tonsils or Down SyndromeObstructive Sleep Apnea of Child
NCT05154214Oregon Health and Science University30
Completed
Phase 3
A Study of Safety and the Local Anesthetic Effect of AG-920 Ophthalmic Solution in a Pediatric PopulationAnesthesia, Local
NCT05325853American Genomics, LLC61